Molecular mechanisms underlying the effects of statins in the central nervous system

Amelia J. McFarland, Shailendra Anoopkumar-Dukie, Devinder S. Arora, Gary D. Grant, Catherine M. McDermott, Anthony V. Perkins, Andrew K. Davey

Research output: Contribution to journalReview articleResearchpeer-review

60 Citations (Scopus)

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins’ effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins’ effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins’ possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.

Original languageEnglish
Pages (from-to)20607-20637
Number of pages31
JournalInternational Journal of Molecular Sciences
Volume15
Issue number11
DOIs
Publication statusPublished - 10 Sep 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
central nervous system
Neurology
Central Nervous System
strokes
Neurodegenerative diseases
Coenzymes
Pharmacokinetics
Nervous System Diseases
disorders
epilepsy
coenzymes
cognition
Cognition Disorders
Stroke
inhibitors
cancer
Primary Prevention
Dyslipidemias
Secondary Prevention

Cite this

McFarland, A. J., Anoopkumar-Dukie, S., Arora, D. S., Grant, G. D., McDermott, C. M., Perkins, A. V., & Davey, A. K. (2014). Molecular mechanisms underlying the effects of statins in the central nervous system. International Journal of Molecular Sciences, 15(11), 20607-20637. https://doi.org/10.3390/ijms151120607
McFarland, Amelia J. ; Anoopkumar-Dukie, Shailendra ; Arora, Devinder S. ; Grant, Gary D. ; McDermott, Catherine M. ; Perkins, Anthony V. ; Davey, Andrew K. / Molecular mechanisms underlying the effects of statins in the central nervous system. In: International Journal of Molecular Sciences. 2014 ; Vol. 15, No. 11. pp. 20607-20637.
@article{29adcf0f857a4a8fb7a376cc32944ebc,
title = "Molecular mechanisms underlying the effects of statins in the central nervous system",
abstract = "3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins’ effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins’ effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins’ possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.",
author = "McFarland, {Amelia J.} and Shailendra Anoopkumar-Dukie and Arora, {Devinder S.} and Grant, {Gary D.} and McDermott, {Catherine M.} and Perkins, {Anthony V.} and Davey, {Andrew K.}",
year = "2014",
month = "9",
day = "10",
doi = "10.3390/ijms151120607",
language = "English",
volume = "15",
pages = "20607--20637",
journal = "International Journal of Molecular Sciences",
issn = "1422-0067",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

McFarland, AJ, Anoopkumar-Dukie, S, Arora, DS, Grant, GD, McDermott, CM, Perkins, AV & Davey, AK 2014, 'Molecular mechanisms underlying the effects of statins in the central nervous system' International Journal of Molecular Sciences, vol. 15, no. 11, pp. 20607-20637. https://doi.org/10.3390/ijms151120607

Molecular mechanisms underlying the effects of statins in the central nervous system. / McFarland, Amelia J.; Anoopkumar-Dukie, Shailendra; Arora, Devinder S.; Grant, Gary D.; McDermott, Catherine M.; Perkins, Anthony V.; Davey, Andrew K.

In: International Journal of Molecular Sciences, Vol. 15, No. 11, 10.09.2014, p. 20607-20637.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Molecular mechanisms underlying the effects of statins in the central nervous system

AU - McFarland, Amelia J.

AU - Anoopkumar-Dukie, Shailendra

AU - Arora, Devinder S.

AU - Grant, Gary D.

AU - McDermott, Catherine M.

AU - Perkins, Anthony V.

AU - Davey, Andrew K.

PY - 2014/9/10

Y1 - 2014/9/10

N2 - 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins’ effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins’ effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins’ possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.

AB - 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly referred to as statins, are widely used in the treatment of dyslipidaemia, in addition to providing primary and secondary prevention against cardiovascular disease and stroke. Statins’ effects on the central nervous system (CNS), particularly on cognition and neurological disorders such as stroke and multiple sclerosis, have received increasing attention in recent years, both within the scientific community and in the media. Current understanding of statins’ effects is limited by a lack of mechanism-based studies, as well as the assumption that all statins have the same pharmacological effect in the central nervous system. This review aims to provide an updated discussion on the molecular mechanisms contributing to statins’ possible effects on cognitive function, neurodegenerative disease, and various neurological disorders such as stroke, epilepsy, depression and CNS cancers. Additionally, the pharmacokinetic differences between statins and how these may result in statin-specific neurological effects are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=84910143418&partnerID=8YFLogxK

U2 - 10.3390/ijms151120607

DO - 10.3390/ijms151120607

M3 - Review article

VL - 15

SP - 20607

EP - 20637

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1422-0067

IS - 11

ER -